Clinical Advances in Hematology & Oncology

Clinical Advances in Hematology & Oncology Clinical Advances in Hematology & Oncology (CAH&O) is a monthly peer-reviewed journal published by Millennium Medical Publishing. Clinical Advances in Hematology & Oncology (CAH&O), is a monthly peer-reviewed journal reaching nearly 26,000 hematology and oncology clinicians.

CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology–including thought leader-driven feature-length review articles, monthly columns comprised of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, and drug development. CAH&O also publishes industry-supported Meeting Highlights, Clinical Roundtable Monographs, and Clinical Review Supplements. Both the journal and all affiliated supplements are included in the National Library of Medicine’s PubMed/MEDLINE index as well as EMBASE.

The July issue of Clinical Advances in Hematology & Oncology is available on our site.
07/23/2019
Current Issue – Hematology & Oncology

The July issue of Clinical Advances in Hematology & Oncology is available on our site.

  H&O What is prostate-specific membrane antigen (PSMA), and what makes it a good target for staging and treatment in prostate cancer? MH PSMA is a […]

The February issue is available on our website
03/01/2019
Hematology & Oncology – Hematology & Oncology

The February issue is available on our website

  H&O How does the National Institute for Health and Care Excellence assign value to drugs and select the ones that will be covered by the […]

The November issue is now available on our site
11/19/2018
Hematology & Oncology – Hematology & Oncology

The November issue is now available on our site

  H&O How common is human epidermal growth factor receptor 2 (HER2) amplification in metastatic colorectal cancer (mCRC)? KR HER2 amplification is found in approximately 3% […]

The October issue of Clinical Advances in Hematology & Oncology is available on our website
10/09/2018
Hematology & Oncology – Hematology & Oncology

The October issue of Clinical Advances in Hematology & Oncology is available on our website

  H&O What are some ethical concerns regarding the typical design of clinical trials in oncology? JK The risk/benefit ratio is an important concern. When treating […]

The August issue is now available on our site
08/22/2018
Hematology & Oncology – Hematology & Oncology

The August issue is now available on our site

  H&O Which patients with melanoma are at elevated risk for a recurrence after surgical resection? JW A patient at elevated risk is one whose 5-year […]

The July issue of Clinical Advances in Hematology & Oncology is available on our website
07/20/2018
Hematology & Oncology – Hematology & Oncology

The July issue of Clinical Advances in Hematology & Oncology is available on our website

  H&O What treatments are available for patients with sickle cell disease? KA Sickle cell disease (SCD) can be cured with allogeneic hematopoietic stem cell transplant. […]

See the articles from our newest (June) issue
06/18/2018
MMP Archive – Hematology & Oncology

See the articles from our newest (June) issue

  H&O What is bipolar androgen therapy (BAT)? SD BAT consists of the administration of a high dose of androgen—also called testosterone—in an effort to control […]

The April issue is now available on our website -- check it out!
04/27/2018
Hematology & Oncology – Hematology & Oncology

The April issue is now available on our website -- check it out!

H&O Which patients with AML are at higher risk for relapse? CD Unfortunately, most adult patients with acute myeloid leukemia (AML) will relapse. Features associated […]

Be sure to read the March issue of Clinical Advances in Hematology & Oncology, now on our website
03/21/2018
Current Issue – Hematology & Oncology

Be sure to read the March issue of Clinical Advances in Hematology & Oncology, now on our website

H&O How common is thrombosis in patients being treated for cancer? MS Approximately 20% to 25% of patients with venous thromboembolism (VTE) at a typical […]

Check out the February issue of Clinical Advances in Hematology & Oncology, which is now on our website
02/14/2018
Current Issue – Hematology & Oncology

Check out the February issue of Clinical Advances in Hematology & Oncology, which is now on our website

H&O What is considered the standard adjuvant treatment for stage III BRAF-mutated melanoma? GL The standard treatment for patients with stage III BRAF-mutated melanoma after […]

The January issue of Clinical Advances in Hematology & Oncology is available on our website. https://buff.ly/2s1L2Ri
02/01/2018
Current Issue – Hematology & Oncology

The January issue of Clinical Advances in Hematology & Oncology is available on our website. https://buff.ly/2s1L2Ri

H&O How common is chemotherapy-induced peripheral neuropathy? MS Chemotherapy-induced peripheral neuropathy (CIPN) is almost universal with certain neurotoxic drugs. Two types of therapies are classically […]

Be sure to check out the December issue of Clinical Advances in Hematology and Oncology on our website
01/05/2018
Current Issue – Hematology & Oncology

Be sure to check out the December issue of Clinical Advances in Hematology and Oncology on our website

H&O How common is chemotherapy-induced peripheral neuropathy? MS Chemotherapy-induced peripheral neuropathy (CIPN) is almost universal with certain neurotoxic drugs. Two types of therapies are classically […]

The November issue of Clinical Advances in Hematology & Oncology is on our site
11/17/2017
MMP Archive – Hematology & Oncology

The November issue of Clinical Advances in Hematology & Oncology is on our site

H&O Which patients with colon cancer require adjuvant therapy? AS Patients who are considered to be at high risk for recurrence require adjuvant therapy. This […]

Letter from the Editor: How to treat Hodgkin lymphoma, by Brad S. Kahl, MD
11/01/2017
Letter from the Editor: How to Treat Hodgkin Lymphoma – Hematology & Oncology

Letter from the Editor: How to treat Hodgkin lymphoma, by Brad S. Kahl, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Letter from the Editor: How to Treat Hodgkin Lymphoma Brad S. Kahl, MD Download PDF Last weekend, I attended the 2017 ASH Meeting on Hematologic Malignancies. This is an incredible 2-day meeting organized around a series...

Encorafenib and binimetinib in BRAF-mutated melanoma, with Keith Flaherty, MD
10/30/2017
In the Pipeline: Encorafenib and Binimetinib in BRAF-Mutated Melanoma – Hematology & Oncology

Encorafenib and binimetinib in BRAF-mutated melanoma, with Keith Flaherty, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 In the Pipeline: Encorafenib and Binimetinib in BRAF-Mutated Melanoma Keith Flaherty, MD Professor of Medicine Harvard Medical School Boston, Massachusetts Download PDF H&O What makes the BRAF inhibitor encorafenib plus…

Genomics in advanced prostate cancer, with Maha H. Hussain, MD
10/30/2017
The Role of Genomics in Patients With Advanced Prostate Cancer – Hematology & Oncology

Genomics in advanced prostate cancer, with Maha H. Hussain, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 The Role of Genomics in Patients With Advanced Prostate Cancer Maha H. Hussain, MD Genevieve E. Teuton Professor of Medicine Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago, Illi...

When to initiate treatment in smoldering multiple myeloma, with María-Victoria Mateos, MD
10/27/2017
When to Initiate Treatment in Smoldering Multiple Myeloma – Hematology & Oncology

When to initiate treatment in smoldering multiple myeloma, with María-Victoria Mateos, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 When to Initiate Treatment in Smoldering Multiple Myeloma María-Victoria Mateos, MD, PhD Director of the Myeloma Unit Haematology Department University Hospital of Salamanca Salamanca, Spain Download PDF H&O How is smold...

DNA repair gene mutations in advanced prostate cancer, by Emmanuel S. Antonarakis, MD
10/26/2017
Prognostic and Therapeutic Implications of DNA Repair Gene Mutations in Advanced Prostate Cancer – Hematology & Oncology

DNA repair gene mutations in advanced prostate cancer, by Emmanuel S. Antonarakis, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Prognostic and Therapeutic Implications of DNA Repair Gene Mutations in Advanced Prostate Cancer Michael T. Schweizer, MD, and Emmanuel S. Antonarakis, MD Dr Schweizer is an assistant professor in the Division of Oncology…

Direct-to-consumer advertising of cancer treatments, with Lowell E. Schnipper, MDhttp://www.hematologyandoncology.net/ar...
10/25/2017
Direct-to-Consumer Advertising of Cancer Treatments – Hematology & Oncology

Direct-to-consumer advertising of cancer treatments, with Lowell E. Schnipper, MD
http://www.hematologyandoncology.net/archives/october-2017/direct-to-consumer-advertising-of-cancer-treatments/

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Direct-to-Consumer Advertising of Cancer Treatments Lowell E. Schnipper, MD Theodore and Evelyn Berenson Distinguished Professor of Medicine in the Field of Oncology Harvard Medical School Clinical Director, Cancer Center…

The management of essential thrombocythemia, by Laura C. Michaelis, MD
10/25/2017
Current Challenges in the Management of Essential Thrombocythemia – Hematology & Oncology

The management of essential thrombocythemia, by Laura C. Michaelis, MD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Current Challenges in the Management of Essential Thrombocythemia Ariel Kleman, MD, Arun K. Singavi, MD, and Laura C. Michaelis, MD Corresponding author: Laura C. Michaelis, MD Hematology and Oncology Medical College of Wi...

New approvals for tisagenlecleucel (Kymriah, Novartis) and notuzumab ozogamicin (Besponsa, Pfizer), and reapproval for g...
10/25/2017
Hem/Onc News – Hematology & Oncology

New approvals for tisagenlecleucel (Kymriah, Novartis) and notuzumab ozogamicin (Besponsa, Pfizer), and reapproval for gemtuzumab ozogamicin (Mylotarg, Pfizer)

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 Hem/Onc News Devon Schuyler Download PDF First Gene Therapy Approved for Use in Acute Lymphoblastic Leukemia The US Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah, Novartis), the first chimeric a...

The optimal duration of adjuvant therapy in colon cancer, with Anthony F. Shields, MD, PhD
10/24/2017
What Is the Optimal Duration of Adjuvant Therapy in Colon Cancer? – Hematology & Oncology

The optimal duration of adjuvant therapy in colon cancer, with Anthony F. Shields, MD, PhD

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 What Is the Optimal Duration of Adjuvant Therapy in Colon Cancer? Anthony F. Shields, MD, PhD Professor of Medicine and Oncology Associate Center Director for Clinical Sciences Karmanos Cancer Institute, Wayne State Univer...

How I treat stage IV non–small cell lung cancer in the absence of any actionable oncogenic driver, by Mark A. Socinski, ...
10/23/2017
How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver – Hematology & Oncology

How I treat stage IV non–small cell lung cancer in the absence of any actionable oncogenic driver, by Mark A. Socinski, MD
http://www.hematologyandoncology.net/archives/october-2017/how-i-treat-stage-iv-non-small-cell-lung-cancer-in-the-absence-of-any-actionable-oncogenic-driver/

Clinical Advances in Hematology & Oncology October 2017 - Volume 15, Issue 10 How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Download PDF Overview • T...

The October issue of Clinical Advances in Hematology & Oncology is now available
10/23/2017
MMP Archive – Hematology & Oncology

The October issue of Clinical Advances in Hematology & Oncology is now available

H&O Which patients with colon cancer require adjuvant therapy? AS Patients who are considered to be at high risk for recurrence require adjuvant therapy. This […]

Address

611 Broadway, Rm 310
New York, NY
10012

Opening Hours

Monday 09:00 - 17:00
Tuesday 09:00 - 17:00
Wednesday 09:00 - 17:00
Thursday 09:00 - 17:00
Friday 09:00 - 17:00
Saturday 09:00 - 17:00
Sunday 09:00 - 17:00

Telephone

(212) 995-2211

Alerts

Be the first to know and let us send you an email when Clinical Advances in Hematology & Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Clinical Advances in Hematology & Oncology:

Category

Nearby media companies


Comments

Engage, a nationwide market research company, is conducting a research study on behalf of a major pharmaceutical company regarding the treatment of various types of Non-Hodgkin Lymphomas. The purpose of the study is to gain valuable feedback regarding patient education for oral anti-cancer therapies from RN, NP or PA's. The confidential phone interviews are being conducted July 18-July 27 at your convenience and will last approximately 75 minutes. In appreciation of your time and opinions, you will receive a $250 honorarium. We do not sell or promote anything, the discussion is solely for research purposes. No identifying information will be used. If you are interested, please contact Amanda Angles at 240-206-6298 or via email at [email protected]. Please include your preferred contact number and best time to be reached for a few preliminary questions prior to scheduling. Spaces are limited